![]() ![]() Intuitive user interface with guided workflows to enable operation on every shift. ![]() Remote alerts to notify practitioners test results are available.Independently validated shortest hands-on time in the lab.Random and continuous access and a modular, scalable design to ensure capacity that meets peak season demand.Bi-directional LIS to automate and accelerate order entry and results reporting.The company’s value proposition for ePlex, as outlined by GenMark on the company’s website, is the following: The company believes that they are the only company offering a true, streamlined sample-to-answer solution. The ePlex system software is designed to improve productivity at every level: User-defined comments on results reports to help determine treatment, an integrated scheduling tool, epidemiology reporting to analyze on-board prevalence data, automated QC tracking to ensure accreditation compliance, and HIPAA compliant safeguards. The ePlex system is a sample-to-answer diagnostic system that integrates the entire process from order to report, which means the ability to fully realize the benefits of rapid, multiplex molecular diagnostics. GenMark Diagnostics has a market capitalization of around $700 million and trades for roughly $10 a share. The company’s systems support a wide array of molecular diagnostic tests: Respiratory, blood culture identification, SARS-CoV-2, HCV genotyping, cystic fibrosis genotyping, thrombophilia risk, warfarin sensitivity, and 2C19 genotyping. The company is focused on expanding the clinical value of the system and growing their market share. The cornerstone of GenMark’s long-term opportunity is ePlex systems. GenMark’s proprietary technology includes eSensor detection technology, eSensor XT-8 and ePlex systems. The firm is a leading provider of multiplex molecular diagnostic solutions that improve patient care, enhance vital quality metrics, and lower the cost of care. GenMark Diagnostics ( NASDAQ: GNMK) is a Carlsbad, California,-based diagnostics company that IPOd in 2010. A full analysis is provided in the paragraphs below. Today we take an in-depth look at a small-cap medical diagnostic firm that appears to be one of the few companies benefiting from the COVID-19 pandemic. Rebellion shows too much respect for authority.”― Marty Rubin ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |